Protease profiling of different biofluids in type 1 diabetes mellitus

Clinical Biochemistry

Volumn 45, Issue 18, 2012, Pages 1613-1619

  Caseiro, Armando ^a,b   Ferreira, Rita ^a   Quintaneiro, Cláudio ^c   Pereira, Amélia ^c   Marinheiro, Rosário ^c   Vitorino, Rui ^a   Amado, Francisco ^a  

^a UNIVERSITY OF AVEIRO   (Portugal)

^b POLYTECHNIC INSTITUTE OF COIMBRA   (Portugal)

^c Internal Medicine Service   (Portugal)

Author keywords

Nephropathy; Retinopathy; Saliva; Urine; Zymography LC MS MS

Indexed keywords

AZUROCIDIN; GELATINASE A; GELATINASE B; KALLIKREIN; MICROSOMAL AMINOPEPTIDASE; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; PROTEINASE;

AMINO ACID SEQUENCE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; ENZYME ACTIVITY; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; SALIVA; SERUM; URINE; WESTERN BLOTTING; ZYMOGRAPHY;

BLOTTING, WESTERN; BODY FLUIDS; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 1; DIABETIC NEPHROPATHIES; DIABETIC RETINOPATHY; HUMANS; MASS SPECTROMETRY; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; PEPTIDE HYDROLASES; PROTEOLYSIS; PROTEOMICS; SALIVA;

EID: 84870696333     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2012.08.027     Document Type: Article

References (40)

1. Whiting D.R., Guariguata L., Weil C., Shaw J. Idf diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 2011, 94:311-321.
2. Diabetes, Fact sheet N°312 World Health Organization [Internet], [cited 2012 July 02]. Available from. http://www.who.int/mediacentre/factsheets/fs312/en/index.html.
3. Marcovecchio M.L., Lucantoni M., Chiarelli F. Role of chronic and acute hyperglycemia in the development of diabetes complications. Diabetes Technol Ther 2011, 13:389-394.
4. Olansky L. Advances in diabetes for the millennium: chronic microvascular complications of diabetes. MedGenMed 2004, 6:14.
5. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the epidemiology of diabetes interventions and complications (edic) study. JAMA 2003, 290:2159-2167.
6. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The diabetes control and complications trial research group. N Engl J Med 1993, 329:977-986.
7. Silberring J., Ciborowski P. Biomarker discovery and clinical proteomics. Trends Anal Chem 2010, 29:128.
8. Nathan D.M. Prevention of long-term complications of non-insulin-dependent diabetes mellitus. Clin Invest Med Med Clin Exp 1995, 18:332-339.
9. Bate K.L., Jerums G. 3: Preventing complications of diabetes. Med J Aust 2003, 179:498-503.
10. Rifai N., Gillette M.A., Carr S.A. Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat Biotechnol 2006, 24:971-983.
11. Granelli-Piperno A., Reich E. A study of proteases and protease-inhibitor complexes in biological fluids. J Exp Med 1978, 148:223-234.
12. Thrailkill K.M., Bunn R.C., Moreau C.S., Cockrell G.E., Simpson P.M., Coleman H.N., et al. Matrix metalloproteinase-2 dysregulation in type 1 diabetes. Diabetes Care 2007, 30:2321-2326.
13. Gharagozlian S., Svennevig K., Bangstad H.J., Winberg J.O., Kolset S.O. Matrix metalloproteinases in subjects with type 1 diabetes. BMC Clin Pathol 2009, 9:7.
14. Golubnitschaja O., Jaksche A., Moenkemann H., Yeghiazaryan K., Karl S.E., Trog D., et al. Molecular imaging system for possible prediction of active retinopathy in patients with diabetes mellitus. Amino Acids 2005, 28:229-237.
15. McKittrick I.B., Bogaert Y., Nadeau K., Snell-Bergeon J., Hull A., Jiang T., et al. Urinary matrix metalloproteinase activities: biomarkers for plaque angiogenesis and nephropathy in diabetes. Am J Physiol Renal Physiol 2011, 301:F1326-F1333.
16. Findeisen P., Neumaier M. Functional protease profiling for diagnosis of malignant disease. Proteomics Clin Appl 2012, 6:60-78.
17. Vitorino R., Barros A., Caseiro A., Domingues P., Duarte J., Amado F. Towards defining the whole salivary peptidome. Proteomics Clin Appl 2009, 3:528-540.
18. Caseiro A., Vitorino R., Barros A.S., Ferreira R., Calheiros-Lobo M.J., Carvalho D., et al. Salivary peptidome in type 1 diabetes mellitus. Biomed Chromatogr 2012, 26:571-582.
19. Mannello F. Effects of blood collection methods on gelatin zymography of matrix metalloproteinases. Clin Chem 2003, 49:339-340.
20. Fingleton B., Menon R., Carter K.J., Overstreet P.D., Hachey D.L., Matrisian L.M., et al. Proteinase activity in human and murine saliva as a biomarker for proteinase inhibitor efficacy. Clin Cancer Res 2004, 10:7865-7874.
21. Makowski G.S., Ramsby M.L. Calibrating gelatin zymograms with human gelatinase standards. Anal Biochem 1996, 236:353-356.
22. Yan L., Borregaard N., Kjeldsen L., Moses M.A. The high molecular weight urinary matrix metalloproteinase (mmp) activity is a complex of gelatinase b/mmp-9 and neutrophil gelatinase-associated lipocalin (ngal). Modulation of mmp-9 activity by ngal. J Biol Chem 2001, 276:37258-37265.
23. Korkmaz B., Attucci S., Epinette C., Pitois E., Jourdan M.L., Juliano L., et al. Measurement of neutrophil elastase, proteinase 3, and cathepsin g activities using intramolecularly quenched fluorogenic substrates. Methods Mol Biol 2012, 844:125-138.
24. Villanueva J., Nazarian A., Lawlor K., Yi S.S., Robbins R.J., Tempst P. A sequence-specific exopeptidase activity test (sseat) for "functional" biomarker discovery. Mol Cell Proteomics 2008, 7:509-518.
25. Klingler D., Hardt M. Profiling protease activities by dynamic proteomics workflows. Proteomics 2012, 12:587-596.
26. Szanto I., Mark L., Bona A., Maasz G., Sandor B., Gelencser G., et al. High-throughput screening of saliva for early detection of oral cancer: a pilot study. Technol Cancer Res Treat 2012, 11:181-188.
27. Jou Y.J., Lin C.D., Lai C.H., Chen C.H., Kao J.Y., Chen S.Y., et al. Proteomic identification of salivary transferrin as a biomarker for early detection of oral cancer. Anal Chim Acta 2010, 681:41-48.
28. Minarowska A., Minarowski L., Karwowska A., Sands D., Dabrowska E. The activity of cathepsin d in saliva of cystic fibrosis patients. Folia Histochem Cytobiol 2007, 45:165-168.
29. Hanemaaijer R., Visser H., Konttinen Y.T., Koolwijk P., Verheijen J.H. A novel and simple immunocapture assay for determination of gelatinase-b (mmp-9) activities in biological fluids: saliva from patients with sjogren's syndrome contain increased latent and active gelatinase-b levels. Matrix Biol 1998, 17:657-665.
30. Mantyla P., Buduneli E., Emingil G., Tervahartiala T., Pussinen P.J., Baris N., et al. Acute myocardial infarction elevates serine protease activity in saliva of patients with periodontitis. J Periodontal Res 2012, 47:345-353.
31. Collin H.L., Sorsa T., Meurman J.H., Niskanen L., Salo T., Ronka H., et al. Salivary matrix metalloproteinase (mmp-8) levels and gelatinase (mmp-9) activities in patients with type 2 diabetes mellitus. J Periodontal Res 2000, 35:259-265.
32. Luis-Rodriguez D., Martinez-Castelao A., Gorriz J.L., De-Alvaro F., Navarro-Gonzalez J.F. Pathophysiological role and therapeutic implications of inflammation in diabetic nephropathy. World J Diabetes 2012, 3:7-18.
33. Kim S.S., Song S.H., Kim I.J., Yang J.Y., Lee J.G., Kwak I.S., et al. Clinical implication of urinary tubular markers in the early stage of nephropathy with type 2 diabetic patients. Diab Res Clin Pract 2012, 97(2):251-257.
34. Thrailkill K.M., Moreau C.S., Cockrell G.E., Jo C.H., Bunn R.C., Morales-Pozzo A.E., et al. Disease and gender-specific dysregulation of ngal and mmp-9 in type 1 diabetes mellitus. Endocrine 2010, 37:336-343.
35. Luan Y., Xu W. The structure and main functions of aminopeptidase n. Curr Med Chem 2007, 14:639-647.
36. Mitic B., Lazarevic G., Vlahovic P., Rajic M., Stefanovic V. Diagnostic value of the aminopeptidase n, n-acetyl-beta-d-glucosaminidase and dipeptidylpeptidase iv in evaluating tubular dysfunction in patients with glomerulopathies. Ren Fail 2008, 30:896-903.
37. Ligoudistianou C., Xu Y., Garnier G., Circolo A., Volanakis J.E. A novel human complement-related protein, c1r-like protease (c1r-lp), specifically cleaves pro-c1s. Biochem J 2005, 387:165-173.
38. Miller J.J., Changaris D.G., Levy R.S. Angiotensin carboxypeptidase activity in urine from normal subjects and patients with kidney damage. Life Sci 1991, 48:1529-1535.
39. Choi Y.J., Heo S.H., Lee J.M., Cho J.Y. Identification of azurocidin as a potential periodontitis biomarker by a proteomic analysis of gingival crevicular fluid. Proteome Sci 2011, 9:42.
40. Carneiro L.G., Venuleo C., Oppenheim F.G., Salih E. Proteome data set of human gingival crevicular fluid from healthy periodontium sites by multidimensional protein separation and mass spectrometry. J Periodontal Res 2012, 47:248-262.